Adding Fovinaciclib to Aromatase Inhibitor Significantly Prolongs Progression-Free Survival in HR+ERBB2- Breast Cancer
A recent clinical trial published in JAMA Oncology has demonstrated that the addition of fovinaciclib, a small-molecule inhibitor targeting proteins essential for tumor cell proliferation, to standard aromatase inhibitor therapy (letrozole or anastrozole) yields a clinically meaningful benefit for patients with hormone receptor-positive, ERBB2-negative (HR+ERBB2-) breast cancer.
Study Design and Scope
The multi-center, randomized, double-blind, placebo-controlled trial was conducted across 63 cancer treatment centers in China. A total of 417 women were enrolled in the study:
- 208 patients received fovinaciclib in combination with an aromatase inhibitor.
- 207 patients received a placebo in combination with an aromatase inhibitor.
Key Findings
At a pre-determined interim analysis (average follow-up of 16.6 months), the fovinaciclib group had not yet reached median progression-free survival, while the placebo group had a median progression-free survival of 16.4 months. The difference was statistically significant.
The researchers reported that the improvement in progression-free survival was achieved with "minimal unexpected adverse events." Due to the small number of deaths at the time of analysis, overall survival data could not yet be assessed.
Clinical Context
Breast cancer remains the most prevalent malignancy among women in the United States, accounting for an estimated 32% of new cancer diagnoses in women this year.
Approximately 70% of breast cancer cases are HR+ERBB2-, meaning the cancer cells express estrogen receptors, progesterone receptors (or both), and do not overexpress the ERBB2 (HER2) protein.
Aromatase inhibitors work by blocking the conversion of androgens to estrogen, a key growth driver in HR+ breast cancer, making them a cornerstone of treatment for this subtype.
Expert Conclusion
"Adding fovinaciclib to an aromatase inhibitor led to a clinically meaningful prolongation of progression-free survival with minimal unexpected adverse events."
The researchers concluded that this combination therapy represents a promising new treatment option for patients with HR+ERBB2- breast cancer, warranting further investigation into overall survival benefits.